ScienceDaily: Health & Medicine News

---

• First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC
• Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer
• Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment
• Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression
• Nivolumab maintains function, reduces symptoms in treatment of relapsed metastatic head and neck cancer
• Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer
• True burden of head and neck cancer in France underestimated by more than one-third
• 70% of advanced cancer patients receive palliative care consultation at ESMO Designated Centers
• Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
• Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify responders
• Ribociclib improves progression-free survival in advanced breast cancer
• Targeting estrogen receptor improves progression-free survival in advanced breast cancer
• Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma
• Immunotherapy shows promising results in first, second line treatment of metastatic bladder cancer
• Kids' consumption of high-calorie drinks at fast-food restaurants tied to combo meals
• Mystery of bacteria's antibiotic resistance unravelled
• African-American, Hispanic men less likely to get treatment for prostate cancer, even with high-risk disease
• UK's approach to health needs radical rethinking, experts say
• Study supports do not sell voluntary waiting period for gun sales to reduce suicide
• Food-poisoning bacteria may be behind Crohn's disease
• Pseudomonas aeruginosa: The molecular tools of a bacterial survivor
• Global burden of disease study 2015 assesses the state of the world's health

First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC Posted: 09 Oct 2016 05:50 AM PDT The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.

Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer Posted: 09 Oct 2016 05:50 AM PDT Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.

Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment Posted: 09 Oct 2016 05:50 AM PDT Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression Posted: 09 Oct 2016 05:50 AM PDT Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.

Nivolumab maintains function, reduces symptoms in treatment of relapsed metastatic head and neck cancer Posted: 09 Oct 2016 05:50 AM PDT Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer Posted: 09 Oct 2016 05:50 AM PDT The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.

True burden of head and neck cancer in France underestimated by more than one-third Posted: 08 Oct 2016 10:48 AM PDT A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to research.

70% of advanced cancer patients receive palliative care consultation at ESMO Designated Centers Posted: 08 Oct 2016 10:48 AM PDT Seven out of ten patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres of Integrated Oncology and Palliative Care, according to survey results.

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial Posted: 08 Oct 2016 10:48 AM PDT The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.

Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify responders Posted: 08 Oct 2016 10:48 AM PDT The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen. The novel compound uses messenger RNA (mRNA) in tumours to identify patients who will respond.

Ribociclib improves progression-free survival in advanced breast cancer Posted: 08 Oct 2016 10:48 AM PDT The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers report.

Targeting estrogen receptor improves progression-free survival in advanced breast cancer Posted: 08 Oct 2016 10:48 AM PDT Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers report.

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma Posted: 08 Oct 2016 10:48 AM PDT Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results.

Immunotherapy shows promising results in first, second line treatment of metastatic bladder cancer Posted: 08 Oct 2016 10:48 AM PDT Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials.

Kids' consumption of high-calorie drinks at fast-food restaurants tied to combo meals Posted: 07 Oct 2016 07:17 PM PDT A new survey of children's and teenagers' eating habits at fast-food restaurants suggests that consumption levels of sugary drinks are closely tied to their automatic inclusion in "combo meal" packages.

Mystery of bacteria's antibiotic resistance unravelled Posted: 07 Oct 2016 07:17 PM PDT The first detailed biochemical characterization of a flavoenzyme involved in antibiotic resistance has now been revealed by scientists.

African-American, Hispanic men less likely to get treatment for prostate cancer, even with high-risk disease Posted: 07 Oct 2016 07:17 PM PDT African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research.

UK's approach to health needs radical rethinking, experts say Posted: 07 Oct 2016 07:11 PM PDT As the NHS lurches from crisis to crisis, the UK's approach to health needs radical rethinking to create a healthy and health-creating society. Just as the founding of the NHS in 1948 was a great national movement creating a health service for everyone, today all sectors of society – from employers, teachers, designers, manufacturers, as well as citizens, community groups and government – need to come together to improve the health of the nation.

Study supports do not sell voluntary waiting period for gun sales to reduce suicide Posted: 07 Oct 2016 12:25 PM PDT A new study suggests many patients at risk for suicide would voluntarily place their name on a Do Not Sell list, prohibiting gun shops from immediately selling them a firearm.

Food-poisoning bacteria may be behind Crohn's disease Posted: 07 Oct 2016 11:03 AM PDT People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study.

Pseudomonas aeruginosa: The molecular tools of a bacterial survivor Posted: 07 Oct 2016 08:10 AM PDT The bacteria Pseudomonas aeruginosa can thrive in environments as different as the moist, warm tissue in our lungs, and the dry, nutrient-deprived surface of an office wall. Such adaptability makes it problematic in healthcare -- where it causes infections in cases of cystic fibrosis, cancer, HIV, and other immune-compromised conditions -- but also makes it a fascinating subject for study.

Global burden of disease study 2015 assesses the state of the world's health Posted: 06 Oct 2016 07:25 AM PDT Researchers have completed the most up-to-date analysis on the state of the world's health to equip governments and donors with evidence to identify national health challenges and priorities for intervention. This massive effort brings together 1870 independent experts in 127 countries and territories as part of the Global Burden of Disease, Injuries, and Risk Factors (GBD) 2015 study collaboration.

You are subscribed to email updates from Health & Medicine News -- ScienceDaily. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States